Request Demo
Recent blog posts
Latest Hotspot
8 min read
Charcot-Marie-Tooth disease type 2A Indication Strategy Report 2026: MFN2, Trials and Deals
24 July 2026
2026 Charcot-Marie-Tooth disease type 2A strategy: epidemiology, MFN2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Emery-Dreifuss muscular dystrophy Indication Strategy Report 2026: LMNA, Trials and Deals
24 July 2026
2026 Emery-Dreifuss muscular dystrophy strategy: epidemiology, LMNA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital muscular dystrophy Indication Strategy Report 2026: LAMA2, Trials and Deals
24 July 2026
2026 Congenital muscular dystrophy strategy: epidemiology, LAMA2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Oculopharyngeal muscular dystrophy Indication Strategy Report 2026: PABPN1, Trials and Deals
24 July 2026
2026 Oculopharyngeal muscular dystrophy strategy: epidemiology, PABPN1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Myotonic dystrophy type 1 Indication Strategy Report 2026: DMPK, Trials and Deals
24 July 2026
2026 Myotonic dystrophy type 1 strategy: epidemiology, DMPK biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Facioscapulohumeral muscular dystrophy Indication Strategy Report 2026: DUX4, Trials and Deals
24 July 2026
2026 Facioscapulohumeral muscular dystrophy strategy: epidemiology, DUX4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Limb-girdle muscular dystrophy Indication Strategy Report 2026: FKRP, Trials and Deals
24 July 2026
2026 Limb-girdle muscular dystrophy strategy: epidemiology, FKRP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Paroxysmal kinesigenic dyskinesia Indication Strategy Report 2026: PRRT2, Trials and Deals
24 July 2026
2026 Paroxysmal kinesigenic dyskinesia strategy: epidemiology, PRRT2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Episodic ataxia type 1 Indication Strategy Report 2026: KCNA1, Trials and Deals
24 July 2026
2026 Episodic ataxia type 1 strategy: epidemiology, KCNA1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 12 Indication Strategy Report 2026: PPP2R2B, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 12 strategy: epidemiology, PPP2R2B biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 17 Indication Strategy Report 2026: TBP, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 17 strategy: epidemiology, TBP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 8 Indication Strategy Report 2026: ATXN8OS, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 8 strategy: epidemiology, ATXN8OS biology, clinical competition, recent deals, unmet need and market attractiveness.